Mercer Global Advisors
URGN icon

Mercer Global Advisors’s UroGen Pharma URGN Stock Holding History

Mercer Global Advisors’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$173K Buy
+4,705
New +$128K ﹤0.01% 3383

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

Mercer Global Advisors's URGN Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in UroGen Pharma (URGN) in Q2 2026: 4,705 shares worth $173K. The stake represents ﹤0.01% of the portfolio and ranks #3383 among its holdings.

174 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • Mercer Global Advisors held 4,705 shares of UroGen Pharma worth $173K as of Q2 2026.
  • UroGen Pharma was a new Mercer Global Advisors position in Q2 2026.
  • UroGen Pharma made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #3383 holding.
  • 174 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.